Sativex® (nabiximols) cannabinoid oromucosal spray in patients with resistant multiple sclerosis spasticity: the Belgian experience

BACKGROUND: This retrospective study evaluates patient-reported outcomes in patients with multiple sclerosis (MS) spasticity who were treated with a cannabinoid oromucosal spray (Sativex®, USAN name: nabiximols) after not sufficiently responding to previous anti-spasticity medications. METHODS: Of 2...

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Julkaisussa:BMC Neurol
Päätekijät: D’hooghe, Marie, Willekens, Barbara, Delvaux, Valerie, D’haeseleer, Miguel, Guillaume, Daniel, Laureys, Guy, Nagels, Guy, Vanderdonckt, Patrick, Van Pesch, Vincent, Popescu, Veronica
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: BioMed Central 2021
Aiheet:
Research
Linkit:https://ncbi.nlm.nih.gov/pmc/articles/PMC8218396/
https://ncbi.nlm.nih.gov/pubmed/34157999
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12883-021-02246-0
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!

Samankaltaisia teoksia